3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Hemorrhage
2
Hematologic Neoplasms
2
Thrombocytopenia
1
Postoperative Hemorrhage
1
Pelvic Mass
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Colonic Neoplasms
1
Breast Neoplasms
1
Breast Cancer Females
1
Brain Neoplasms
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tranexamic Acid
×
1 year
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled